Citigroup Inc Sera Prognostics, Inc. Transaction History

Citigroup Inc

$196 Billion
Q2 2025

A detailed history of Citigroup Inc transactions in Sera Prognostics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 5 shares of SERA stock, worth $12. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 20,342 99.98%

Holding current value

$12

Previous $74,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$1.49 - $3.46 $30,302 - $70,366	-20,337 Reduced 99.98%	5 $0
Q1 2025 May 12, 2025	SELL	$3.54 - $8.33 $8,060 - $18,967	-2,277 Reduced 10.07%	20,342 $74,000
Q4 2024 Feb 12, 2025	BUY	$6.03 - $8.83 $16,226 - $23,761	2,691 Added 13.5%	22,619 $196,000
Q3 2024 Nov 12, 2024	BUY	$5.29 - $8.43 $73,652 - $117,370	13,923 Added 231.86%	19,928 $155,000
Q2 2024 Aug 12, 2024	SELL	$5.6 - $11.69 $75,773 - $158,177	-13,531 Reduced 69.26%	6,005 $35,000
Q1 2024 May 10, 2024	SELL	$5.05 - $10.0 $251,555 - $498,130	-49,813 Reduced 71.83%	19,536 $177,000
Q4 2023 Feb 09, 2024	BUY	$1.65 - $6.85 $114,425 - $475,040	69,349 New	69,349 $414,000
Q4 2022 Feb 09, 2023	SELL	$1.16 - $1.8 $395 - $613	-341 Reduced 78.94%	91 $0
Q3 2022 Nov 10, 2022	SELL	$1.55 - $2.71 $249 - $436	-161 Reduced 27.15%	432 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.2 - $3.62 $597 - $1,802	-498 Reduced 45.65%	593 $1,000
Q1 2022 May 12, 2022	SELL	$2.96 - $8.8 $2,646 - $7,867	-894 Reduced 45.04%	1,091 $4,000
Q4 2021 Feb 10, 2022	BUY	$6.87 - $11.41 $9,906 - $16,453	1,442 Added 265.56%	1,985 $14,000
Q3 2021 Nov 10, 2021	BUY	$7.9 - $13.04 $4,289 - $7,080	543 New	543 $6,000

Others Institutions Holding SERA

# of Institutions

Shares Held

22.4M

Call Options Held

12.3K

Put Options Held

100

View Full List

About SERA PROGNOSTICS, INC.

Ticker SERA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 29,596,900
Market Cap $74.6M
Description
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product ...

More about SERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account